Sharemaestro Newsreel

Globus Medical (NYSE:GMED) Beats Q2 CY2026 Sales Expectations

Globus Medical (NYSE:GMED) Beats Q2 CY2026 Sales Expectations Medical device company Globus Medical (NYSE:GMED) announced better-than-expected revenue in Q2 CY2026, with sales up 5.9% year on year to $789.6 million. The company expects the full year's revenue to be around $3.2 billion, close to …

Profound Medical Corp (PROF) Earnings Forecast: Future EPS & Revenue Growth Estimates

Profound Medical (PROF) reported Q2 earnings of $0.26 per share, significantly surpassing the Zacks Consensus Estimate of a loss of $0.22 per share. While the company beat EPS estimates, its revenues of $2.48 million for the quarter missed the consensus estimate by 55.66%. The …

QT Imaging Holdings Inc (QTI) Earnings Forecast: Future EPS & Revenue Growth Estimates

Co-Diagnostics' Test Filing Draws on 1,400 Patients

Co-Diagnostics (Nasdaq: CODX) has submitted a Dual FDA 510(k) premarket notification and a concurrent CLIA Waiver by Application for its Co-Dx PCR Flu A/B & RSV upper respiratory multiplex test. This test is designed for use on the Co-Dx PCR Pro instrument in decentralized …

Co-Diagnostics submits FDA 510(k) for respiratory test

Co-Diagnostics, Inc. has submitted a Dual 510(k) premarket notification and a concurrent CLIA Waiver by Application to the FDA for its Co-Dx PCR Flu A/B & RSV upper respiratory multiplex test. This submission aims to allow the test to be used in decentralized point-of-care …

LENSAR Inc (LNSR) Stock News Today

This article provides current stock information for LENSAR Inc (LNSR), including its stock price, market capitalization, and P/E ratio. It indicates that more news regarding the company's stock, earnings, and analyst ratings will be available soon. The page serves as a hub for financial …

Sera Prognostics (SERA) Q1 2026 Earnings: EPS Matches Estimates at -$0.17, Stock Flat - Guidance Upgrade Report

How Does electroCore Inc (ECOR) Measure Up After Q2 Earnings? EP

RxSight, Inc. Stock 12‑Month Price Target Cut to $7.91, Implies 26% Upside

RxSight, Inc.'s average stock price target has been reduced from $8.06 to $7.91 by 8 analysts, with individual forecasts ranging from $6 to $11 per share. This new target suggests a potential upside of approximately 26% based on the recent closing price. The consensus …

Senseonics Holdings, Inc. 2026: Revenue $14.48M, EPS ($0.63) — 10-Q Summary

Senseonics Holdings, Inc. (SENS) reported a significant increase in revenue to $14.48M for the 2026 quarter, up 117.8% year-over-year, driven by U.S. consignment expansion and demand for its Eversense 365 product. Despite the revenue growth, the company posted a net loss of ($36.71M) and …

Senseonics Holdings Inc earnings missed by $0.02, revenue topped estimates

Senseonics Holdings Inc (NASDAQ: SENS) reported its second-quarter earnings, missing analyst EPS estimates by $0.02 with an EPS of $-0.630, while revenue surpassed expectations at $14.5M against an estimated $13.36M. The company's stock has seen fluctuations, being up 1.790% in the last three months …

ElectroCore, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

ElectroCore, Inc. reported its second-quarter and six-month earnings results for the period ended June 30, 2026. For the second quarter, sales increased to $9.45 million from $7.38 million year-over-year, and the net loss narrowed to $3.06 million from $3.67 million. For the six months, …

Standard BioTools (LAB) Stock Rebound Leaves Revenue Slide And Losses In Focus

Standard BioTools (LAB) saw a slight stock rebound after its Q2 2026 earnings, but this is overshadowed by a 7.6% revenue decline to US$20.1 million and persistent losses, despite a narrower net loss from continuing operations. The market is waiting for sustained top-line growth …

QuidelOrtho (Nasdaq: QDEL) trims 2026 revenue and EPS guidance

QuidelOrtho (Nasdaq: QDEL) has reported its second-quarter 2026 results, showing a 2.8% year-over-year revenue increase to $630.9 million but a GAAP net loss of $92.9 million. The company has trimmed its full-year 2026 financial guidance, reducing expected revenue, adjusted EBITDA, and adjusted EPS, and …

Avita Medical upgrades FY26 revenue guidance

Avita Medical announced a reduced statutory net loss of USD7.7 million for the June quarter and updated its full-year 2026 net revenue guidance to between USD86 million and USD89 million, an increase from its previous forecast. The company also anticipates achieving cashflow breakeven in …

Cerus Corp (CERS) Earnings Forecast: Future EPS & Revenue Growth Estimates

Cerus Corp (CERS) has an earnings forecast score of 8.67, ranking 17th in its industry, with an average analyst price target of $5.00, suggesting a 113.09% upside. Based on 3 analysts, the stock is rated as a "Buy." The company's expected revenue for the …

Profound Medical (NASDAQ: PROF) Q2 loss narrows as revenue rises

Profound Medical Corp. reported a Q2 2026 revenue of $2.5 million, marking a 12% year-over-year increase, with gross margin expanding to 78% and operating expenses falling by 16%. The company's net loss improved by 39% to $9.5 million, or $0.26 per share, and it …

Is Senseonics Holdings Inc (SENS) a Value Trap After Q2 Earnings? Revenue Hits $14.5M with GF Score of 56/100

180 Wealth Advisors LLC Lowers Holdings in Medtronic PLC $MDT

180 Wealth Advisors LLC significantly reduced its stake in Medtronic PLC (NYSE:MDT) by 75% in the second quarter, selling 29,822 shares and retaining 9,951 shares valued at $778,000. Despite this reduction, Medtronic reported strong quarterly results with revenue of $9.81 billion and adjusted EPS …

Balefire LLC Sells 25,744 Shares of Medtronic PLC $MDT

Balefire LLC significantly reduced its stake in Medtronic PLC (NYSE:MDT) by 67.1% in the second quarter, selling 25,744 shares but still retaining 12,614 shares valued at $987,000. Despite this institutional sell-off and recent price target reductions by analysts, Medtronic holds a "Moderate Buy" consensus …

Lifeward to Report Second Quarter 2026 Financial Results on August 14, 2026

Lifeward Ltd. (Nasdaq: LFWD) announced it will report its second quarter 2026 financial results on Friday, August 14, 2026. A press release will be issued and a quarterly report filed with the SEC before 9:30 a.m. ET, though no conference call will be held. …

Cytek Biosciences (CTKB) holders report over 7% stakes in Schedule 13G/A

Millennium-affiliated entities and Israel A. Englander have filed an amended Schedule 13G/A, disclosing significant ownership stakes in Cytek Biosciences, Inc. Integrated Core Strategies (US) LLC reported a 5.5% beneficial ownership, while Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each reported …

Enovis Corporation 2026 Q2 - Results - Earnings Call Presentation (NYSE:ENOV) 2026-08-07

CeriBell Inc (CBLL) Earnings Forecast: Future EPS & Revenue Growth Estimates

Tandem Diabetes Care (NASDAQ: TNDM) lifts Q2 sales to $254.6M, trims loss

Tandem Diabetes Care reported strong second-quarter 2026 results, with worldwide sales increasing by 6% to $254.6 million and a significant improvement in gross margin to 57%. The company also narrowed its GAAP net loss to $21.2 million and achieved positive Adjusted EBITDA of $6.4 …

The Manufacturers Life Insurance Company Sells 65,658 Shares of Penumbra, Inc. $PEN

The Manufacturers Life Insurance Company significantly reduced its stake in Penumbra, Inc. by selling 65,658 shares, now holding 20,047 shares valued at $6.6 million. Despite collective institutional ownership of 88.88%, analyst sentiment for Penumbra is mixed with a "Hold" consensus and a target price …

PODD Shareholder Alert: August 31, 2026 Lead Plaintiff Deadline in Insulet Corporation Securities Class Action - Contact SueWallSt

This article announces a lead plaintiff deadline of August 31, 2026, for a securities class action lawsuit against Insulet Corporation (NASDAQ: PODD). The lawsuit alleges that Insulet made misleading statements regarding its manufacturing quality after two voluntary medical device corrections led to significant drops …

Pacific Biosciences of California, Inc. Stock 12‑Month Price Target Cut to $2.29, Implies 76% Upside

The average 12-month price target for Pacific Biosciences of California, Inc. (PACB) stock has been lowered from $2.46 to $2.29 by 6 analysts, suggesting a potential upside of approximately 76% from its August 5th closing price. Despite the target cut, the consensus rating from …

Amundi Increases Stock Position in Bruker Corporation $BRKR

Amundi increased its stake in Bruker Corporation (NASDAQ:BRKR) by 244.2% in the first quarter, now holding 62,611 shares valued at $2.26 million. Despite the company beating EPS estimates for Q2 2026 with $0.49 per share, its revenue of $838.5 million missed analyst expectations, raising …

DexCom Inc. Stock Sheds 4.9%, Underperforms Market

The article reports that DexCom Inc. (DXCM) stock experienced a 4.9% decline, leading to its underperformance in the market. The brief notice, sourced from Dow Jones, indicates a negative movement for the company's shares. Further details require a user to log in.

About 40% of Treace’s Lapiplasty surgeon users use new systems

Treace Medical Concepts reported a 4% decline in Q2 2026 revenue to $45.4 million year-over-year, alongside a net loss of $15.9 million. Despite the revenue dip, the company saw an 8% reduction in operating expenses and significantly decreased year-to-date cash usage by 57%. Treace …

Tandem Earnings: Few Surprises as the Firm Makes Progress With Mobi Pump

RxSight (RXST) Stock Faces Margin Strain After Guidance Withdrawal

Sanuwave Health (SNWV) to Release Quarterly Earnings on Friday

Smith & Nephew Earnings: Weakness in First Half Could Linger in Second Half

Artivion Q2 Earnings Call Highlights

Key Points Interested in Artivion, Inc.? Here are five stocks we like better. Artivion's Q2 revenue rose 9% to $125.8 million on a constant-currency basis, driven by 12% growth in stent grafts and 18% growth in On-X valves. Adjusted EBITDA increased 7% to $26.4 …